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Abstract
Objectives The aim of this work was to examine the cross-sectional relationship between body composition (BC) markers for adipose
and lean tissue and bone mass, and a wide range of specific inflammatory and adipose-related markers in healthy elderly Europeans.
Methods Awhole-body dual-energy X-ray absorptiometry (DXA) scan was made in 1121 healthy (65–79 years) women and
men from five European countries of the BNew dietary strategies addressing the specific needs of elderly population for a healthy
aging in Europe^ project (NCT01754012) cohort to measure markers of adipose and lean tissue and bone mass. Pro-
inflammatory (IL-6, IL-6Rα, TNF-α, TNF-R1, TNF-R2, pentraxin 3, CRP, alpha-1-acid glycoprotein, albumin) and anti-
inflammatory (IL-10, TGF-β1) molecules as well as adipose-related markers such as leptin, adiponectin, ghrelin, and resistin
were measured by magnetic bead-based multiplex-specific immunoassays and biochemical assays.
Results BC characteristics were different in elderly women and men, and more favorable BC markers were associated with a
better adipose-related inflammatory profile, with the exception of skeletal muscle mass index. No correlation was found with the
body composition markers and circulating levels of some standard pro- and anti-inflammatory markers like IL-6, pentraxin 3, IL-
10, TGF-β1, TNF-α, IL-6Rα, glycoprotein 130, TNF-α-R1, and TNF-α-R2.
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Conclusions The association between BC and inflammatory and adipose-related biomarkers is crucial in decoding aging and
pathophysiological processes, such as sarcopenia. DXA can help in understanding how the measurement of fat and muscle is
important, making the way from research to clinical practice.
Key Points
• Body composition markers concordantly associated positively or negatively with adipose-related and inflammatory markers,
with the exception of skeletal muscle mass index.
• No correlation was found with the body composition markers and circulating levels of some standard pro- and
anti-inflammatory markers like IL-6, pentraxin 3, IL-10, TGF-β1, TNF-α, IL-6Rα, gp130, TNF-α-R1, and TNF-α-R2.
• Skeletal muscle mass index (SMI) shows a good correlation with inflammatory profile in age-related sarcopenia.
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Abbreviations
AGP Alpha-1-acid glycoprotein
ALMI Appendicular lean mass index
BC Body composition
BMC Bone mineral content
BMD Bone mineral density
CVD Cardiovascular disease
DXA Dual-energy X-ray absorptiometry
FM Fat mass
FMI Fat mass index
gp130 Glycoprotein 130
hsCRP High-sensitivity C-reactive protein
IL Interleukin
IL-6Rα Interleukin-6 receptor alpha
LOA Low obesity A
LOB Low obesity B
LM Lean mass
LMI Lean mass index
MO Moderate obesity
NW Normal weight
OWA Overweight A
OWB Overweight B
SMI Skeletal muscle mass index
TGF-β1 Transforming growth factor beta 1
TNF-α Tumor necrosis factor alpha
TNF-α-R TNF-α receptor
Introduction
The assessment of body composition (BC) is essential for
the characterization of metabolic status [1]. The changes in
BC that occur with aging are mainly related to three distinct
processes: (i) a progressive decrease in lean mass (LM) and
an increase in fat mass (FM) potentially leading to
sarcopenia and sarcopenic obesity [2]; (ii) a redistribution
of FM, central and visceral [3]; and (iii) a reduction in body
height and bone mineral density (BMD) [4, 5]. Excessive
body fat accumulation is an established risk factor for a
multitude of chronic conditions, including insulin resistance
and type 2 diabetes, cardiovascular disease (CVD), and cer-
tain cancers, that are among the major causes of deaths in
US and European population [6, 7]. Metabolic diseases are
character ized by an inf lammatory status cal led
metaflammation, a particular case of chronic inflammation
driven by nutrient excess/overnutrition [8]. Recently, it has
been hypothesized that metaflammation may precede/
contribute to inflammaging, i.e., the chronic, low-grade, sys-
temic, inflammatory state that characterizes aging [9, 10],
and that metabolic age-related dysfunctions and diseases
can be considered manifestations of aging acceleration
[11]. Levels of major circulating pro-inflammatory cyto-
kines, e.g., the tumor necrosis factor alpha (TNF-α), inter-
leukin (IL)-1 family, IL-6, and IL-8, are increased in both
conditions [12]. Interestingly, inflammaging does not simply
reflect an increase of pro-inflammatory markers but an over-
all activation of inflammatory systems that probably also
promotes a concomitant rise in the levels of anti-
inflammatory mediators [13, 14]. As adipose tissue expands
and muscle and bone tissue decrease during aging, there is
an increase in pro-inflammatory and a reduction in anti-
inflammatory adipokines, chemokines, and cytokines which
contributes to local and systemic inflammation and distur-
bances in glucose homeostasis [15]. However, studies on the
relationship between composition and regional distribution
of adipose and lean tissue and bone mass and the relative
inflammatory profile in healthy elderly subjects are almost
completely missing. A widely used technique for the assess-
ment of human BC [16] is represented by dual-energy X-ray
absorptiometry (DXA) [1, 17]. In the current study, we
aimed to evaluate associations of several inflammatory and
adipose-related hormones with adipose, lean tissue, and
bone mineral content measured by DXA in a representative
sample of European 65+-year-old healthy adults participat-
ing in the BNew dietary strategies addressing the specific
needs of elderly population for a healthy aging in Europe^
(NU-AGE) study. Such relationships are of interest in clini-
cal practice to investigate the role of inflammation and re-
gional body composition markers in aging, sarcopenia, and
obesity-related diseases.
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Materials and methods
Study design and participants
NU-AGE (http://www.nu-age.eu/) was a 1-year, multicenter,
randomized, single-blind, controlled trial (registered with
clinicaltrials.gov, NCT01754012) with two parallel groups (i.e.,
dietary intervention and control). The recruitment was carried out
in five European centers in France, Italy, the Netherlands, Poland,
and the United Kingdom (UK). The recruitment of participants
has been described in detail previously [18–20]. Briefly, 2668
volunteers from the community aged 65–79 years, free of major
overt chronic diseases, living independently, and free of dementia,
were recruited to participate in the baseline assessment. Of the
2668 participants, 1512 were screened for inclusion and 1296
were eligible to participate in the NU-AGE trial. In this study,
we included 1121 participants who completed the baseline
DXA assessment in the five recruiting centers (France (N= 184;
16.4%), Italy (N= 236; 21%), the Netherlands (N= 233; 20.7%),
Poland (N= 222; 19.8%), and UK (N= 246; 21.9%)).
Assessment of body composition
Awhole-body DXA scan was performed to measure total and
regional body composition using the fan-beam densitometers
described in the supplementary methods section.
Regions of interest were defined by the analytical software
including six different corporeal districts: total body, trunk,
upper limbs, lower limbs, android region (a portion of the
abdomen included between the line joining the two superior
iliac crests and extended cranially up to the 20% of the dis-
tance between this line and the chin), and gynoid region (a
portion of legs from the femoral great trochanter, directed
caudally up to a distance double of the android region).
Android and gynoid regions were not defined by the densi-
tometer used in the UK. For each region, DXA scanned the
weight (in g) of total mass, FM, non-bone LM, and bone
mineral content (BMC). The relationship between parameters
derived from the different DXA machines was investigated
using specific reliable indexes. In particular, total body FM/
LM (a), fat mass index (FMI, whole-body fat mass/heigth2)
(b), lean mass index (LMI, whole-body lean mass/heigth2) (c),
android/gynoid FM (d), android FM/LM (e), appendicular
lean mass index (ALMI, lean mass from arms plus
legs/height2) (f), and skeletal muscle mass index (SMI, lean
mass from arms plus legs/weight) (g) were considered as the
pivotal markers of body composition, in terms of general mass
balance (a, b, c), central/peripheral distribution of FM (d),
central abdominal distribution (e), and low muscle mass (f,
g), respectively. Moreover, BMD and T-score were also con-
sidered as markers of bone health [21].
In order to identify specific body composition profiles among
the participants a cluster analysis was performed separately
within women and men using the following ten BC markers:
FM, FMI, LM, LMI, ALMI, FM/LM, SMI, T-score, BMC,
and BMD in combination with BMI; the results of this analysis
are described in [21]. Briefly, five clusters were identified for
women (normal weight (NW), BMI = 21.39; overweight A
(OWA), BMI = 25.09; overweight B (OWB), BMI = 26.62;
low obesity A (LOA), BMI = 31.48; and low obesity B (LOB),
BMI = 31.92) and six for men (NW, BMI = 23.98; OWA,
BMI = 25.69; OWB, BMI = 26.27; LOA, BMI = 30.06; LOB,
BMI = 30.42; and moderate obesity (MO), BMI = 36.6). These
are able to discriminate groups of subjects with significantly
different body composition markers when the BMI is very sim-
ilar [22] (Supplementary Table 1).
Statistical methods
According to the Shapiro–Wilk test for normality (p< .01), we
decided to use non-parametric statistical tests. R project (version
3.3.3 for Windows) was used for the analysis, and results are
reported as mean and standard deviation (± SD). Data were ana-
lyzed byMann–Whitney and Kruskal–Wallis tests to determinate
differences between men and women and between clusters [21].
We also used pairwise comparisons to test differences between all
pairs of clusters. A type I error of .05 (p value) in two-tailed tests
was considered significant. To assess a possible linear association
between the body composition variables and markers of inflam-
mation, we used the Pearson product-moment correlation, after a
natural log-transformation (ln) for BC variables and a log-odds
transformation for markers of inflammation. Due to multiple test-
ing of the variables, the Benjamini–Hochberg correction was ap-
plied and both p value and q value are reported in BResults.^
Results
Participant characteristics
One thousand one hundred twenty-one subjects, 620 women
(55%) and 501 men (45%), from the NU-AGE cohort were
included in this study. Almost all the anthropometric, metabolic
measures and the body composition markers considered were
significantly different between men and women (Table 1), and
for this reason, all the analyses were stratified by sex. Men had
higher height, weight, waist circumference, waist-to-hip ratio,
calorie intake, and glucose and hemoglobin levels than women
(p < .05 for all). Women had significantly higher fat mass
markers than men in terms of FM, FMI, FM/LM, and android
FM/LM but lower android/gynoid FM. Conversely, men had
significantly higher lean mass markers than women in terms of
LM, ALMI, LMI, and SMI, and higher BMC and BMD than
women. Higher levels of ghrelin, leptin, adiponectin, resistin, and
alpha-1-acid glycoprotein (AGP) were found in women, but
there was no sex difference for IL-6, pentraxin 3, IL-10,
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TGF-β1, TNF-α, IL-6Ra, glycoprotein 130 (gp130), TNF-α-
R1, and TNF-α-R2 circulating levels (Supplementary Table 2A
and B, Supplementary Methods).
Association of body composition with markers
of inflammation and adipose-related hormones
Significant associations of BC markers with inflammation
and adipose-related hormones are summarized in
Supplementary Table 3A and B. In elderly women, a negative
correlation between ghrelin and adiposity was found, but not
in men, where ghrelin showed a positive correlation with
SMI. In both women and men, leptin showed strong positive
associations with fat mass, while weak positive associations
with lean mass and bone mass markers. A strong negative
association was observed with SMI in both sexes. Resistin
was not associated with any BC marker in both women and
men, while no associations with BC markers were found in
Table 1 Characteristics of participants by sex (n = 1121)
Women (n = 620) Men (n = 501) p value q value
Age (years) 70.7 ± 3.9 71.0 ± 4.1 NS NS
Weight (kg) 67.7 ± 11.2 80.6 ± 12.6 < 2.2e−16 < 2.2e−16
Height (cm) 160.0 ± 6.7 173.0 ± 6.4 < 2.2e−16 < 2.2e−16
BMI (kg/m2) 26.5 ± 4.1 26.9 ± 3.7 1.16e−02 NS
Hip circumference (cm) 103.3 ± 9.1 101.5 ± 7.6 1.32e−03 NS
Waist circumference (cm) 86.9 ± 10.8 96.7 ± 11.1 < 2.2e−16 < 2.2e−16
Waist-to-hip ratio 0.85 ± 0.31 0.95 ± 0.06 < 2.2e−16 < 2.2e−16
Calorie intake (kcal) 1680.9 ± 327.8 2123.3 ± 445.0 < 2.2e−16 < 2.2e−16
PASE score 127.8 ± 48.9 140.9 ± 59.5 3.53e−04 NS
Metabolic parameters
Glucose 5.52 ± 0.77 5.85 ± 0.95 7.92e−11 1.54e−07
Insulin 8.75 ± 5.57 10.03 ± 7.85 NS NS
HOMA IR 2.21 ± 1.58 2.70 ± 2.36 5.47e−03 NS
HOMA beta 90.43 ± 52.88 89.06 ± 63.57 2.08e−02 NS
Hemoglobin (g/dl) 13.7 ± 0.9 14.9 ± 1.0 < 2.2e−16 5.66e−14
Body composition markers
FM (kg) 26.2 ± 8.06 22.0 ± 8.37 < 2.2e−16 < 2.2e−16
FMI (kg/m2) 10.3 ± 3.16 7.35 ± 2.74 < 2.2e−16 < 2.2e−16
LM (kg) 40.3 ± 4.97 57.1 ± 6.71 < 2.2e−16 < 2.2e−16
ALMI (kg/m2) 6.56 ± 0.77 8.47 ± 0.87 < 2.2e−16 < 2.2e−16
LMI (kg/m2) 15.7 ± 1.53 19.1 ± 1.80 < 2.2e−16 < 2.2e−16
FM/LM 0.65 ± 0.19 0.39 ± 0.14 < 2.2e−16 < 2.2e−16
SMI 0.25 ± 0.03 0.32 ± 0.04 < 2.2e−16 < 2.2e−16
BMC (g) 2092.5 ± 357 2947.8 ± 483 < 2.2e−16 < 2.2e−16
BMD (g/cm2) 1.03 ± 0.11 1.19 ± 0.11 < 2.2e−16 < 2.2e−16
T-score − 0.82 ± 1.20 − 0.19 ± 1.20 < 2.2e−16 4.92e−14
Android/gynoid FM* 0.50 ± 0.15 0.78 ± 0.21 < 2.2e−16 < 2.2e−16
Android FM/LM* 0.79 ± 0.30 0.61 ± 0.25 2.70e−16 4.92e−13
Inflammatory parameters
Ghrelin (pg/ml) 1631.46 [842.57–4427.87] 1256.32 [582.13–3538.03] 9.86e−05
Leptin (ng/ml) 4.39 [2.86–6.21] 1.86 [0.94–3.16] < 2.2e−16 < 2.2e−16
Adiponectin (μg/ml) 14.09 [9.76–19.96] 7.33 [5.03–10.51] < 2.2e−16 < 2.2e−16
Resistin (pg/ml) 5850.83 [4287.64–7520.41] 6222.25 [4756.82–8310.03] 5.67e−03
CRP (mg/l) 0.87 [0.44–1.72] 0.84 [0.41–1.78] NS NS
AGP (mg/ml) 0.67 [0.57–0.79] 0.61 [0.51–0.73] 1.24e−08 2.32e−05
Albumin (g/l) 44.90 [42.50–47.50] 44.95 [42.78–48.00] NS NS
NS not significant
* (Women, n = 474; Men, n = 416)
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women with albumin and in men with AGP. Pairwise scatter
plots reporting all the correlations between these markers in
women and in men are shown in Figs. 1 and 2, respectively.
As expected, there were significant correlations between all
of the body composition markers; in particular, all the fat
mass, lean mass, and bone markers are positively related,
while the SMI is negatively correlated with the fat mass
markers BMI, FM, FMI, and FM/LM in both female and
male elderly subjects as reported in the upper left part of the
pairwise scatter matrix plot in Figs. 1 and 2.
No significant correlation was found between the body com-
position markers and the following pro- and anti-inflammatory
markers in both female andmale elderly subjects: IL-6, pentraxin
3, IL-10, TGF-β1, TNF-α, IL-6Rα, gp130, TNF-α-R1, and
TNF-α-R2 (Supplementary Table 2A and B).
Markers of inflammation and adiposity were also correlated
with android FM/LM and android/gynoid FM (Tables 2 and 3).
In women, positive correlations with android FM/LM and
android/gynoid FM were found for leptin, CRP, and AGP; pos-
itive associations were only found for leptin and CRP in men.
Android FM/LM and android/gynoid FM were negatively cor-
related with ghrelin, adiponectin, and albumin in women, while
in men, a negative association was found with adiponectin.
Association of markers of inflammation
and adipose-related hormones with body
composition clusters
Inflammatory markers and adipose-related hormones were al-
so evaluated in relation to clusters of body composition
markers that have been previously identified by the authors
[22] (Supplementary Fig. 1).
Among the five clusters identified in women, there is a
significant difference for ghrelin (p = 5.297e−06),
adiponectin (p = 2.829e−06), CRP (p = 1.154e−12), leptin
(p < 2.2e−16), AGP (p = 1.651e−12), and TGF-β1
(p = .005) (Fig. 3). Ghrelin levels are higher in the NW
cluster compared with the OWB and LOB clusters, and
the levels in the OWA are also higher than those in the
LOB (Fig. 3a). Leptin levels are lower in the NW cluster
of women compared with all the other four clusters, and
interestingly, the LOB has significantly higher leptin
levels than the LOA (Fig. 3b). Women belonging to the
NW cluster have higher levels of adiponectin compared
with OWA, LOA, and LOB (Fig. 3c). The levels of CRP
are lower in the NW cluster compared with all the other
four clusters (Fig. 3d). The levels of AGP are lower in the
NW cluster compared with all the other four clusters
(Fig. 3e). Among the five clusters identified in women,
the levels of TGF-β1 are significantly different between
NW and LOB (Fig. 3f).
Among the six clusters identified in men, there is a
significant difference for ghrelin (p = .0006417),
adiponectin (p = .0005453), CRP (p = 1.174e−06), leptin
(p < 2.2e−16) , a lbumin (p = .004843) , and AGP
(p = .001147) (Fig. 4). In particular, ghrelin levels are sig-
nificantly higher in the NW cluster compared with the
LOB (Fig. 4a). Leptin levels are lower in the NW cluster
of men compared with the OWB, LOA, LOB, and MO
(Fig. 4b). Adiponectin levels are higher in elderly men
Fig. 1 Pairwise scatter plot matrix. Histogram and correlation
coefficients of all body composition parameters and inflammatory
parameters in women. Pairwise scatter plots are in the lower triangle
boxes, histograms are in the diagonal boxes, and correlation coefficients
between variables are in the upper triangle boxes
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belonging to the NW cluster compared with the LOB
cluster (Fig. 4c). CRP and AGP levels are significantly
lower in elderly men compared with the NW and LOB
clusters, OWA and LOB clusters, and OWB and LOB
clusters (Fig. 4d, e). Albumin is significantly higher in
the LOA compared with the LOB elderly men (Fig. 4f).
Discussion
The present study reports evidence for an association between
body composition markers assessed by DXA and the concen-
tration of a number of pro- and anti-inflammatory parameters
as well as adipose-related hormones. Although DXA does not
provide a direct measurement of FM, LM, and BMC, it is
widely used for BC assessment in both clinical and research
settings, because of its good values of accuracy and precision,
large availability, low costs, low radiation dose, and good
correlations with BC measurements obtained by CT and
MRI [21, 23–25].
Although several studies have shown specific associations
with central and/or peripheral fat mass, BMI and waist cir-
cumference, and inflammatory molecules such as IL-1Rα,
IL-6, and IL-6-sR [26–28], we did not find any correlation
with the body composition markers and indexes studied and
circulating levels of a series of pro- and anti-inflammatory
molecules such as IL-6, pentraxin 3, IL-10, TGF-β1,
TNF-α, IL-6Rα, gp130, TNF-α-R1, and TNF-α-R2. This
difference could be explained by the size of the cohort used,
by the technique used to identify body composition and many
other factors.
As expected, major differences exist between BC charac-
teristics in elderly women and men. Elderly women have
higher fat mass than men while men have higher lean mass
and bone content than elderly women. Sex dimorphism in
total body composition is present at birth and continues
through adulthood [29]. Men maintain their lean mass into
the fifth decade of life but then begin to lose muscle mass
due to both hormonal changes, decline in activity levels, low
protein diet, reduced blood flow, and decreased nerve conduc-
tion. Women show a similar decline in lean mass, but they
often show greater gains in fatness [29], even when weight
is stable [30]. Such changes continue into old age [4, 31].
Among the adipose-related markers, ghrelin, which is con-
sidered an anti-inflammatory molecule, is negatively associat-
ed with fat mass in women but not in men, while it is posi-
tively associated with SMI in both sexes. Ghrelin levels are
reported to fall in obesity, with concentration influenced prin-
cipally by changes in energy balance. Insulin, in particular,
may play an important role in the decrease of ghrelin levels
after meals [32]. Even if BMI and insulin are not different
between sexes, women have greater fat mass than men, and
this could explain the different associations found. Also when
comparing the ghrelin levels among the five clusters previous-
ly identified by the authors [22] which differ for BMI and fat
mass and lean mass and bone density, a sex difference
emerged. In women, the levels of ghrelin decrease as BMI
clusters increase from normal weight to low obesity clusters.
Fig. 2 Pairwise scatter plot matrix. Histogram and correlation
coefficients of all body composition parameters and inflammatory
parameters in men. Pairwise scatter plots are in the lower triangle
boxes, histograms are in the diagonal boxes and correlation coefficients
between variables are in the upper triangle boxes
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In both men and women, leptin is positively associated
with fat mass, lean mass, and bone mass markers, while it is
negatively associated with SMI. Leptin is a classic adipokine
that is secreted by adipocytes, and it increases with weight
gain and decreases with weight loss and is also considered
as a pro-inflammatory marker [33]. Recent studies have re-
ported, however, that leptin is also produced by skeletal mus-
cle [34, 35] as well as bone cells [36]. Leptin treatment in-
creases muscle mass and decreases the expression of atrophy-
related factors such as myostatin, muscle RING-finger pro-
tein-1 (MuRF1), and muscle atrophy F-box (MAFbx) in mus-
cle [37] without any change with age. More recent studies
show that the effects of leptin on the skeleton are quite com-
plex, and that leptin deficiency is associated with low bone
mass primarily due to reduced cortical bone [38, 39]. Central
infusions of leptin in leptin-deficient ob/ob mice actually in-
crease cortical bone formation and total bone mass [40].
Individuals with osteoporosis have reduced levels of leptin
in the bone marrow microenvironment [41].
Adiponectin, together with leptin, is able to regulate energy
homeostasis. Low levels of adiponectin, that is considered an
anti-inflammatory mediator, have been found in obesity and
insulin resistance [15]. In our cohort, both men and women
show an inverse relationship with fat and lean mass markers.
Our results are in agreement with a recent paper by Baker and
colleagues [42] showing that in elderly, high levels of serum
adiponectin are correlated with low BMI, fat, and lean mass
BCmarkers.Moreover, adiponectin levels decrease as clusters
increase BMI in both sexes. However, it is interesting to note
that in women when comparing clusters with similar BMI
(25.09 and 26.62, respectively), adiponectin levels are higher
in the overweight group with higher levels of fat and bone
mass and lower levels of lean mass. In men, the levels of
adiponectin are generally not different among the six clusters.
It has been reported that an increase in fat mass is correlated
with markers of inflammation among community-dwelling
individuals older than 65 years [26, 27]. The mechanisms
inducing obesity-related inflammation are not completely un-
derstood; however, the expansion of adipose tissue in re-
sponse to a positive energy balance may play a major role.
When adipose tissue expands, it leads to the activation of
macrophages which secrete inflammatory cytokines including
TNF-α and IL-6 [43]. In addition, leptin together with resistin
could also function as a pro-inflammatory molecule in the
presence of obesity [44], while adiponectin and ghrelin have
anti-inflammatory properties. In particular, adiponectin is
known to inhibit inflammation by blocking NF-kB activation
and reducing such cytokines as TNF-α, IL-6, and IL-18 [45,
46]. Moreover, adiponectin may also play a pro-inflammatory
role in arthritic joints by promoting COX2 expression and the
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Fig. 3 a–f Box plots and
significant differences of
inflammatory and adipose-related
markers among clusters in women
(p values: *p ≤ .05, **p ≤ .01,
***p ≤ .001)
Eur Radiol
synthesis of PGE2, which increases inflammation and pain
[47]. Through the elaboration of anti- and pro-inflammatory
adipokines that enter the systemic circulation, adipose tissue
plays a critical role in regulating the inflammatory response in
the setting of calorie restriction, obesity, and aging. However,
it is possible that the association with inflammatory markers
differs by sex and by adipose tissue location. The most com-
monly measured inflammatory proteins in nutrition surveys
are CRP, which is a measure of acute inflammation, and
AGP, which is a measure of chronic inflammation [48]. In
our study, CRP correlated with fat mass in both sexes, but
only in women with LMI and ALMI. CRP and AGP levels
gradually increased as the BMI increased in the clusters in
women. It has been shown that the effects of aging on the
human immune system are significantly different in men and
women, showing a stronger pro-inflammatory response in
women [49]. Even if in our study any difference emerged in
CRP concentrations between men and women (median
0.84 mg/l and 0.87 mg/l, respectively), women have a signif-
icantly higher concentration of AGP compared to men (medi-
an 0.67 g/l and 0.61 g//l, respectively). Indeed, AGP was
positively correlated with fat markers and LMI only in wom-
en. Hemoglobin levels were also significantly lower in women
than in men (median 13.7 g/dl and 14.9 g/dl, respectively),
and these lower levels of iron could possibly further contribute
to the different inflammatory status [48] between men and
women. CRP acts as a positive and albumin as a negative
acute-phase reactant [50]. This seems to provide a link to the
already mentioned, slightly increased inflammatory state in
elderly women. In this context, it is interesting that several
clinical studies could demonstrate a link between the specific
pattern of increased CRP and decreased albumin concentra-
tions with sarcopenia, frailty, and vascular and non-vascular
mortality in elderly subjects [50–52].
Among the body composition markers, SMI associates dif-
ferently from the others with the adipose-related and inflamma-
tory markers analyzed in this study. SMI represents a marker of
sarcopenia, together with ALMI [53, 54]. In our cohort, the
associations of SMI with adipose-related and inflammatory
markers studied are always discordant in both women and
men, the only exception being the positive correlation with
albumin levels in men. In particular, in both women and men,
SMI correlated positively with ghrelin, which is considered an
anti-inflammatory molecule, but negatively with leptin, CRP,
and AGP, which are considered pro-inflammatory markers. As
inflammation is thought to have a role in age-related sarcopenia
[55], the results obtained with SMI are more consistent with
respect to those obtained with ALMI when both are considered
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as markers of sarcopenia. These results fit with the open debate
on the use of optimal quantitative markers of sarcopenia and the
role of imaging [53, 56]. Moreover, SMI is inversely correlated
with BMI and fat mass markers and positively with ALMI but
not with LM and LMI, while ALMI is positively correlated
with BMI and fat mass markers and also with LM and LMI.
These results showed that it is likely that ALMI still represents
the general lean mass instead of being a marker of sarcopenia;
however, further studies are needed to verify this hypothesis.
These last results could be of help in the prevention of
sarcopenia.
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